Danielle Valletti, Assistant Editor

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.

A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.

Phase 3 findings from the VIKTORIA-1 trial demonstrated clinically meaningful progression-free survival improvements with gedatolisib-based regimens in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

A recent report of liver failure in a patient receiving orforglipron has renewed attention on the long-term safety monitoring of GLP-1 receptor agonists.

Explore updates around hantavirus outbreak and FDA controversies.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

Expanding education, safety responsibilities, and patient support roles are elevating the importance of pharmacy technicians in cancer care.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.

The FDA approved the supplemental biologics license for the expansion of IVIG (immune globulin, intravenous) use to children 2 years and older with primary humoral immunodeficiency, enabling earlier treatment and infection protection.

FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Pharmacists help prevent communication breakdowns and improve coordination across oncology care teams.

The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment

Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.

Pharmacists are central to implementing bispecific antibody therapies through clinical expertise, operational leadership, and care coordination.

Pharmacists support evidence-based treatment decisions, coordinate multidisciplinary care, and optimize precision oncology outcomes.

Integrated EMR systems and coordinated pharmacy operations can streamline biomarker-driven treatment decisions and improve patient outcomes.

Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.

Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

How community oncology practices are expanding access to innovative therapies while navigating reimbursement and care delivery challenges.

Pharmacists must remain in a constant state of readiness by implementing structured shortage management plans and guiding patients through access challenges as supply disruptions persist.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.

Global trade disruptions and reliance on overseas manufacturing could contribute to future drug shortages, highlighting the need for proactive planning and supply chain resilience across pharmacy settings.